Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Increases By 20.7%

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 1,040,000 shares, a growth of 20.7% from the March 31st total of 861,800 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average trading volume of 429,400 shares, the days-to-cover ratio is currently 2.4 days.

Analysts Set New Price Targets

A number of analysts recently commented on DCTH shares. HC Wainwright lifted their price objective on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Craig Hallum lifted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Delcath Systems presently has an average rating of "Moderate Buy" and an average price target of $22.75.

Delcath Systems Stock Performance

Delcath Systems stock traded up $2.74 during trading on Thursday, reaching $14.35. The company had a trading volume of 1,318,449 shares, compared to its average volume of 364,914. Delcath Systems has a 12-month low of $5.30 and a 12-month high of $16.97. The stock's 50 day moving average price is $12.29 and its two-hundred day moving average price is $12.55. The firm has a market capitalization of $479.76 million, a price-to-earnings ratio of -10.63 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. As a group, research analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds have recently modified their holdings of DCTH. State Street Corp boosted its position in Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company's stock valued at $772,000 after buying an additional 9,400 shares during the last quarter. Jane Street Group LLC acquired a new stake in Delcath Systems during the 3rd quarter valued at approximately $110,000. Barclays PLC purchased a new stake in Delcath Systems during the 3rd quarter worth approximately $104,000. Geode Capital Management LLC raised its position in shares of Delcath Systems by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock valued at $2,275,000 after purchasing an additional 7,298 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $289,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.